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Background/aim: The aim of this research is to investigate the clinical efficacy of hemoperfusion in the treatment of severe acute
organophosphorus pesticide poisoning (AOPP).
Materials and methods: Patients meeting the inclusion criteria were divided into Groups 1 and 2 according to whether hemoperfusion
was applied or not. Group 2 was observed as the control group. Conventional therapy for AOPP was given to Groups 1 and 2. Besides
conventional treatment, patients in Group 1 were also treated with hemoperfusion therapy. Cholinesterase activity and blood glucose
concentration were tested before hemoperfusion and for the first 3 days afterwards. The recovery time of 50% cholinesterase was
recorded. At the same time, the incidence and mortality of intermediate syndrome was observed and compared.
Results: The incidence and mortality of intermediate syndrome in Group 1 was obviously decreased, and the recovery time of
cholinesterase activity was significantly shortened compared with Group 2.
Conclusion: Hemoperfusion, used for treating severe AOPP, contributes to the improvement of cholinesterase activity, low incidence
and mortality of intermediate syndrome, and increase in curative rate.
Key words: Hemoperfusion, severe acute organophosphorus pesticide poisoning, cholinesterase activity

1. Introduction
Acute organophosphorus pesticide poisoning (AOPP)
is a harmful condition that causes death (1). Data
from the World Health Organization indicate that
approximately three million people each year are at risk of
organophosphorus pesticide poisoning (2). Research has
shown that the major mechanism of organophosphorus
pesticide poisoning is the inhibition of organic phosphorus
acting on cholinesterase. This inhibition leads to a large
accumulation of acetylcholine in the tissue space, which
further results in a series of dysfunctions in the nervous
system, myocardial cells, and respiration (3,4). Severe
AOPP can cause acute cholinergic crisis, including the
stimulation of nicotinic receptors and muscarinic receptors,
which leads to the main cause of death, namely respiration
failure (5). Muscarine can induce sympathetic excitement,
stimulate the secretion of glucagon, and elevate the level
of blood glucose (6). Therefore, cholinesterase activity and
blood glucose concentration can be the detection index of
severe AOPP.
At present, the traditional treatment for severe AOPP
is intravenous injection of the anticholinergic drugs
atropine and cholinesterase reactivators. Due to the short
* Correspondence: yuliangzhang112@sohu.com

half-life, large dose, high risk of side effects, and tedious
implementation, patients lack confidence in atropine
therapy (7). Since the 1970s, hemoperfusion has been
applied in the treatment of severe AOPP. With the help of
a solid adsorbent, hemoperfusion can effectively remove
toxic substances and purify blood with obvious clinical
effects, which contributes to patient recovery (8). However,
the clinical efficacy of hemoperfusion has received mixed
reviews. This study was carried out to evaluate the
clinical efficacy of hemoperfusion on severe AOPP by
observing the clinical data of cholinesterase activity and
toxic substance concentrations in the blood in order to
provide a theoretical basis for the clinical application of
hemoperfusion.
2. Materials and methods
2.1. Participants
Patients with severe AOPP admitted to our hospital from
January 2011 to December 2015 were selected as participants.
All patients were orally ingesting organophosphorus
pesticides such as dichlorvos, dimethoate, parathion, and
omethoate. Simultaneously, patients were suffering from
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dottiness or stupor, accompanied by sweating, extreme
narrowing of the pupils, systemic muscle fasciculation,
rales in the lungs, dyspnea, slow heartbeat, arrhythmia,
decrease of blood pressure, irregular gait, and reduction
of whole blood cholinesterase activity below 30%. The
symptoms were in line with the criteria of severe AOPP
established in the seventh edition of the guidelines of the
Department of Internal Medicine. The exclusion criteria
were hypertension or diabetes; allergy to equipment; and
thrombocytopenia, leukopenia, other coagulopathies, or
coma caused by other causes.
2.2. Grouping
Patients treated with hemoperfusion in the clinic were in
the experimental group (Group 1), and an equal number
of patients without hemoperfusion were in the control
group (Group 2). Patients in Groups 1 and 2 were matched
according to complications, admission time, age, and sex.
2.3. Methods
Patients in both Groups 1 and 2 were treated with
conventional AOPP therapy. Patients removed
contaminated clothes, were repeatedly given gastric lavage
and indwelling gastric tubes, and took active carbon and
cathartics. At the early stage of AOPP, patients were given
anticholinergic drugs, cholinesterase reactivators, and
comprehensive treatment including correction of acidbase imbalance, control of infection, and mechanical
ventilation. On the basis of conventional treatment, patients
in Group 1 were treated with hemoperfusion within 3 h of
poisoning. Vascular access was established via a doublecavity central venous catheter and subclavian vein catheter.
Hemoperfusion machine JF-800A and hemoperfusion
apparatus HA330 (Lizhu Medical Biomaterial Co. Ltd.,
Zhuhai, China) were applied in the treatment of AOPP
at 150–200 mL/min for 2 h. Heparin was routinely used
for anticoagulation, and air was used for returning treated
blood after the process. Hemoperfusion was performed
once a day for 3 days.
Cholinesterase
activity
was
detected
by
spectrophotometer before hemoperfusion and in the first
3 days afterwards. The recovery time of 50% cholinesterase
(T50) was recorded. Blood glucose concentration was
detected simultaneously. We observed the incidence and
mortality of intermediate syndrome in the two groups and
compared them during the treatment.
2.4. Statistical analysis
SPSS 21.0 was used to analyze the clinical data. Two-way and
multilevel analyses of variance for repeated measurement
data were used to analyze the measurement data
(cholinesterase activity, toxic substance concentrations,
and blood glucose concentration). Numerical data, such as
intermediate syndrome and cases of death, were analyzed
by chi-square test. There was statistical significance at P
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< 0.05. Statistical figures were drawn according to the
clinical data.
3. Results
In this research, there were 130 patients in Group 1 and
130 in Group 2. There was no statistical difference in age
or sex among patients in Groups 1 and 2 (P > 0.05), which
excludes the effect of age and sex on the results of the study.
3.1. Intermediate syndrome
Intermediate syndrome is a group of syndromes with
respiratory paralysis and muscle paralysis in extremities
of proximal muscle and innervated muscle by cranial
nerves III, IV, and X, caused by postsynaptic nerve–
muscle junction dysfunction (8). In this research, there
were only 5 (3.8%) cases with intermediate syndrome after
hemoperfusion in Group 1. Compared to Group 2 (14,
10.7%), the incidence of intermediate syndrome in Group
1 was significantly reduced and mortality was remarkably
decreased, which had a notable statistical difference (P <
0.05).
3.2. Cholinesterase activity
Cholinesterase activity in the two groups was restored
after treatment. The detected data on cholinesterase
activity showed that it had decreased on the first day but
was restored quickly in the following 2 days. In the same
period, the recovery of cholinesterase activity in Group 1
was much higher than that of Group 2 (P = 0.037 < 0.05),
and the resurrection time of 50% cholinesterase in Group 1
was shorter than in Group 2, with significant differences (P
= 0.023 < 0.05). It demonstrated that the recovery time of
cholinesterase activity in Group 1 was remarkably shorter
compared to Group 2. See Tables 1 and 2 and Figure 1A
for detail.
3.3. Decrease of blood glucose
In the two groups, blood glucose concentration was
significantly decreased after treatment compared to before
treatment. Blood glucose level in the second and third
days after treatment was obviously lower than that before
treatment (P < 0.05). There was no obvious difference in
the comparison between the two groups (P > 0.05). See
Table 3 and Figure 1B for detail.
4. Discussion
It was demonstrated in the research that AOPP could
immediately cause cholinergic crisis and respiratory
muscle paralysis, leading to intermediate syndrome,
central respiratory failure, and acute encephaledema and
finally causing death. Currently, the mortality of drug
treatment for AOPP is 26.2%. Especially for severe AOPP,
drug treatment could result in multiple organ dysfunction
syndromes, which further increase mortality (9,10).
The phosphate radical of organophosphorus
compounds binds irreversibly with cholinesterase in
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Table 1. Clinical data on severe AOPP.

Age, years#, mean ± SD

Group 1 (n = 130)

Group 2 (n = 130)

P

38.5 ± 12.93

39.3 ± 11.67

0.600

Sex*, female (%)

76 (58.5)

71 (54.2)

0.488

Recovery time of 50% cholinesterase, days

5.0 ± 3.2

5.8 ± 2.4

0.023

Intermediate syndrome*, n (%)

5 (3.8)

14 (10.7)

0.033

Mortality*, n (%)

12 (9.2)

25 (19.1)

0.023

#: t-test; *: chi-square test.
Table 2. Comparison of cholinesterase activity in the two groups before and after treatment.

Groups

Before
treatment

Group 1 (n = 130)
Group 2 (n = 130)

Frequency of hemoperfusion
First time
(first day)

Second time
(second day)

Third time
(third day)

18.3 ± 1.9

15.5 ± 2.5

53.2 ± 5.1

76.9 ± 7.4

19.6 ± 2.0

16.6 ± 1.8

46.6 ± 5.9

71.2 ± 8.6

Variance analyses of repeated measurement data were adopted to analyze the data. Pairwise
comparison between the two groups was performed by LSD method after treatment. Comparison
between the two groups: P = 0.037; comparison in time: P < 0.001; interaction: P > 0.05. P-value
among four points in time was less than 0.05 after treatment.

Figure 1. Blood glucose concentration and cholinesterase activity before and after hemoperfusion: A) cholinesterase
activity before and after hemoperfusion; B) blood glucose concentration before and after hemoperfusion. In the figure, 0 on
the horizontal axis means before hemoperfusion and 1, 2, and 3 are the first, second, and third days after hemoperfusion,
respectively. The red line represents the results in Group 1. The green line represents the results in Group 2.

plasma, red blood cells, the central nervous system, and the
peripheral nervous system. This decreases cholinesterase
activity; results in the accumulation of a large amount
of acetylcholine in the body; leads to overexpression of
cholinesterase receptors in the autonomic nervous system,
central nervous system, and synapses of the neuromuscular

junction; and gives rise to a series of clinical symptoms.
Furthermore, dyspnea can appear suddenly in patients,
especially in cases of type II respiration failure, which is
the main cause of death (11,12). Intermediate syndrome
can appear during the recovery from cholinergic crisis
for patients with moderate or severe AOPP (13). The
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Table 3. Comparison of blood glucose concentration in the two groups before and after treatment.

Groups

Before
treatment

Group 1 (n = 130)
Group 2 (n = 130)

Frequency of hemoperfusion
First time
(first day)

Second time
(second day)

Third time
(third day)

8.3 ± 1.84

7.9 ± 2.15

6.5 ± 1.77

5.4 ± 1.76

8.1 ± 2.15

8.0 ± 1.93

6.7 ± 1.91

5.8 ± 1.67

Variance analyses of repeated measurement data were adopted to analyze data. Pairwise comparison
between the two groups was performed by LSD method after treatment. Comparison between the
two groups: P = 0.621; comparison in time: P < 0.001; interaction: P > 0.05. Comparison among four
points in time adopted pairwise comparison after treatment. Comparison between pretreatment
and the first day after treatment gave P ≥ 0.05. When the data before treatment were compared to
those of the second and of the third day after treatment, both P-values were less than 0.05.

main reason is postsynaptic nerve–muscle junction
dysfunction, which causes myasthenia, respiratory muscle
paralysis, and dyspnea, further leading to hypoxia and then
bringing about disturbance of consciousness, coma, and
even death. Therefore, it is vital for severe AOPP patients
to have dissociative and protein- or lipid-combined
toxic substances in the blood removed and recover their
cholinesterase activities. At present, the main drugs
for AOPP are cholinesterase reactivators (pralidoxime,
pralidoxime chloride, etc.) and anticholinergic drugs
(atropine). It is difficult for cholinesterase reactivators to
play a role in the treatment of patients with intermediate
syndrome. Due to the low permeability rate of the blood–
brain barrier, cholinesterase reactivators do not have a
significant effect on the treatment of symptoms caused
by neurological disorders (central respiratory failure,
etc.). Anticholinergics (atropine) have more side effects,
such as a blurred mind, coma, and convulsions, and a
significant effect on muscarinic action, while they have no
alleviating effect on nicotine action (14). Hemoperfusion
could remove toxic substances and purify the blood via
extracorporeal circulation and solid adsorbents. The
hemoperfusion apparatus in this study could not only
absorb dissociative organic phosphorus in the blood
but could also get rid of organic phosphorus that had
combined with protein or lipids (15). It was demonstrated
in the study that hemoperfusion in the treatment of severe
AOPP could obviously shorten the recovery time of
cholinesterase activity, significantly reduce the incidence
of intermediate syndrome and mortality, and enhance cure
rates.

Organic phosphorus pesticide is absorbed into the
blood through the gastrointestinal tract and skin and is then
excreted via the kidney. Due to residual toxic substances
in patients’ gastrointestinal tracts on admission, there
were still some toxic substances absorbed into the blood
at the early stage of treatment. Therefore, cholinesterase
activity within 1 day after patients were admitted to the
hospital decreased to a certain degree compared to that
on admission. Cholinesterase activity of patients gradually
recovered after they were treated with drugs. On the basis
of drug therapy, patients in the hemoperfusion group were
also treated with hemoperfusion to quickly purify their
blood and eliminate toxic substances. This could reduce
the successive injury to patients’ bodies caused by residual
toxic substances, boost the recovery of cholinesterase
activity, and shorten the recovery time of cholinesterase
activity. Blood glucose concentrations of patients with
severe AOPP in the two groups increased, but then
decreased after treatment. Nevertheless, hemoperfusion
has no advantages in the treatment of blood glucose
concentrations.
Hemoperfusion not only reduces the complications
for patients significantly after admission and shortens
hospital stays (16,17), but also decreases fees for nutrition
support, postoperative management, and treatment of
complications. Hemoperfusion can be implemented by the
side of a bed in the hospital, which is simple, economical,
and effective. Due to the significant effect on AOPP,
hemoperfusion improves cure rates, reduces the pain of
patients, and increases hospital income. Hemoperfusion in
the treatment of AOPP is worthy of promotion in clinics.
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